Objectives: Aim of this study was to evaluate the effect of adjuvant therapy on the recurrence and on the
overall survival in patients with early stage endometrioid adenocarcinoma of endometrium and
lymphovascular space invasion (LVSI) treated with primary surgery.
Methods: 48 patients with endometrioid adenocarcinoma of endometrium and LVSI were evaluated in
this retrospective study. The Log-Rank test was used for statistical analyses and the Kaplan-Meyer
method was used for time-to-event analysis.
Results: 14 (29%) received radiotherapy as adjuvant therapy, whereas 34 (71%) did not received any
adjuvant therapy.
Between the patients who underwent adjuvant therapy, 4 (28%) developed a recurrence, the median time
to recurrence was 26 months (8-53) and the median survival after recurrence was 56 months (29-120).
12(50%) patients who had not received any therapy relapsed, the median time to recurrence was 12
months (4-38) and the median survival after recurrence was 30 months (14-93).
The analysis demonstrated that adjuvant therapy is not associated neither to a decreased in the
occurrence of relapse (p=0,2), neither to an increase in survival (p=0,1).
Conclusion: The administration of adjuvant radiotherapy in patients with recurrent endometrioid
adenocarcinoma of early stage endometrial cancer and LVSI does not affect neither the occurrence of
relapse, neither the overall survival
